CAJ | 학술논문

目的：观察DC－CIK细胞免疫疗法联合肝动脉造影化疗栓塞、中药综合治疗肝癌有效性、安全性。方法82例肝癌患者，采用前瞻性、对照、随机方法分为两组。对照组单纯采用肝动脉造影加化疗栓塞术。治疗组在此基础上联合DC－CIK细胞免疫疗法以及中药辨证施治。观察两组治疗前后生活质量变化、临床疗效、生化指标、3年生存率、T细胞亚群指标变化。结果治疗组治疗后总有效率和生活质量均优于对照组（P＜0．05，P＜0．01）。治疗组治疗后ALT、AFP下降较治疗前明显（P＜0．01），且治疗后与对照组比较差异有统计学意义（P＜0．01）。治疗组1－3年的率明显高于对照组（P＜0．05）。治疗组CD3＋、CD4＋、NK细胞比例升高（P＜0．01）。结论 DC－CIK细胞免疫疗法联合介入、中药综合治疗肝癌，能够提高患者的生活质量，增加治疗的有效率，延长患者的生存时间，降低ALT、TBIL、AFP，增强机体的免疫功能，不良反应少、安全性高。
목적：관찰DC－CIK세포면역요법연합간동맥조영화료전새、중약종합치료간암유효성、안전성。방법82례간암환자，채용전첨성、대조、수궤방법분위량조。대조조단순채용간동맥조영가화료전새술。치료조재차기출상연합DC－CIK세포면역요법이급중약변증시치。관찰량조치료전후생활질량변화、림상료효、생화지표、3년생존솔、T세포아군지표변화。결과치료조치료후총유효솔화생활질량균우우대조조（P＜0．05，P＜0．01）。치료조치료후ALT、AFP하강교치료전명현（P＜0．01），차치료후여대조조비교차이유통계학의의（P＜0．01）。치료조1－3년적솔명현고우대조조（P＜0．05）。치료조CD3＋、CD4＋、NK세포비례승고（P＜0．01）。결론 DC－CIK세포면역요법연합개입、중약종합치료간암，능구제고환자적생활질량，증가치료적유효솔，연장환자적생존시간，강저ALT、TBIL、AFP，증강궤체적면역공능，불량반응소、안전성고。
s:Objective To observe the efficacy and safety of DC-CIK cell immunotherapy combined with TACE and traditional Chinese medicineintreatmentoflivercancer.Methods 82casesweredividedintotwogroupsbyprospective,controlled,randomizedmethods.The control group only treated by TACE.The treatment group treated by DC-CIK cell immunotherapy combined with TACE and traditional Chi-nese medicine.To observe the changes in the quality of life, effect, biochemical indexes, the 3 -year survival rate, T lymphocyte subsets. Results The quality of life and the total effective rate in treatment group were changed more obviously( P<0.05) .ALT and AFP of treat-ment group were decreased(P<0.01).The 3 -year survival rate in treatment group was higher than control group (P<0.05).After treat-ment,CD3 +、CD4 +、NK cells in treatment group were increased than that before treatment (P<0.01).Conclusion DC-CIK cell immu-notherapy combined with TACE and traditional Chinese medicine can improve the quality of life, increase the effective rate, prolong the sur-vival time, decrease ALT、TBIL and AFP, enhance the immunity function.It has low side effects and high safety.